{"entity":{"id":"nct06265727","kind":"trial","name":"A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of CRB-701 in advanced solid tumours, run by Corbus Pharmaceuticals Inc., now recruiting.","summary":"A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors is a phase 1/2 interventional study registered as NCT06265727 by Corbus Pharmaceuticals Inc., with 348 participants planned, started 2024-04-01 and due to reach its primary completion in 2027-01-16. Interventions recorded: CRB-701 and Anti-PD-1.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06265727","url":"https://clinicaltrials.gov/study/NCT06265727"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["crb-701"],"companies":["corbus-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06265727","phase":"1/2","setting":"A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CRB-701, an Antibody-drug Conjugate Targeting Nectin-4, in Patients With Advanced Solid Tumors","sponsor":"Corbus Pharmaceuticals Inc.","enrolled":348,"outcomes":[]},"route":"/trials/nct06265727/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"crb-701","kind":"drug","name":"CRB-701","route":"/drugs/crb-701/"}],"company":[{"id":"corbus-pharmaceuticals","kind":"company","name":"Corbus Pharmaceuticals","route":"/companies/corbus-pharmaceuticals/"}]}}